SCHEMBL7918554

SCHEMBL7918554

CN(C)C(=O)COc1c(F)cc(SCCNS(=O)(=O)c2ccccc2)cc1F

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.76
HSD17B10 Q99714 2/20 0.76
CYP1A2 P05177 1/20 0.76
CYP3A4 P08684 1/20 0.76
CYP2C9 P11712 1/20 0.76
NFKB1 P19838 1/20 0.76
PMP22 Q01453 1/20 0.76
HIF1A Q16665 1/20 0.76
GAA P10253 2/20 0.49
TSHR P16473 5/20 0.44
MAPT P10636 4/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
TDP1 Q9NUW8 1/20 0.39
MAPK1 P28482 1/20 0.39
USP2 O75604 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7911825 0.90 ALDH1A1 (0.62) ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9
SCHEMBL21569276 0.90 ALDH1A1 (0.73) ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9
SCHEMBL7921097 0.89 ALDH1A1 (0.60) ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9
SCHEMBL7919297 0.88 ALDH1A1 (0.84) ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9
SCHEMBL18377179 0.88 ALDH1A1 (0.79) ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9
SCHEMBL7918876 0.87 ALDH1A1 (0.74) ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9
SCHEMBL18377355 0.87 ALDH1A1 (0.77) ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9
SCHEMBL20383345 0.87 ALDH1A1 (0.77) ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9
SCHEMBL1171583 0.86 ALDH1A1 (1.00) ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9
SCHEMBL21569318 0.86 ALDH1A1 (0.56) ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3321252-A1 NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR Public University Corporation Yokohama City University (JP) 2018-05-16 EP claimed
US-20200384134-A1 IMAGING METHOD OF AMPA RECEPTORS IN BRAIN OF PRIMATE ORGANISM, PROGRAM, DIAGNOSTIC AGENT, COMPANION DIAGNOSTIC AGENT, DRUG, SCREENING METHOD, INPUT TERMINAL, SERVER AND SYSTEM PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) 2020-12-10 US disclosed
US-20200384134-A1 IMAGING METHOD OF AMPA RECEPTORS IN BRAIN OF PRIMATE ORGANISM, PROGRAM, DIAGNOSTIC AGENT, COMPANION DIAGNOSTIC AGENT, DRUG, SCREENING METHOD, INPUT TERMINAL, SERVER AND SYSTEM PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) 2020-12-10 US disclosed
EP-3321252-B1 NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR PUBLIC UNIV CORP YOKOHAMA CITY UNIV (JP) 2020-10-21 EP disclosed
EP-3569229-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH AMPA RECEPTORS Public University Corporation Yokohama City University (JP) 2019-11-20 EP disclosed
EP-3569255-A1 IMAGING METHOD OF AMPA RECEPTORS IN BRAIN OF PRIMATE ORGANISM, PROGRAM, DIAGNOSTIC AGENT, COMPANION DIAGNOSTIC AGENT, DRUG, SCREENING METHOD, INPUT TERMINAL, SERVER AND SYSTEM Public University Corporation Yokohama City University (JP) 2019-11-20 EP disclosed
EP-3569229-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH AMPA RECEPTORS Public University Corporation Yokohama City University (JP) 2019-11-20 EP disclosed
US-10335503-B2 Compound that specifically binds to AMPA receptor PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) 2019-07-02 US disclosed
US-20180200391-A1 NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) 2018-07-19 US disclosed
EP-3321252-A1 NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR Public University Corporation Yokohama City University (JP) 2018-05-16 EP disclosed
EP-0811375-B1 GLUTAMIC ACID RECEPTOR AGONIST NIPPON SUISAN KAISHA LTD (JP) 2001-01-03 EP disclosed
US-5955505-A TREATING NERVE DEGENERATIVE DISORDERS NIPPON SUISAN KAISHA, LTD. (JP) 1999-09-21 US disclosed
EP-0811375-A1 GLUTAMIC ACID RECEPTOR AGONIST NIPPON SUISAN KAISHA, LTD. (JP) 1997-12-10 EP disclosed
EP-0469901-B1 Sulfonamide derivatives TAISHO PHARMACEUTICAL CO LTD (JP) 1994-10-19 EP disclosed
US-5189211-A Thromboxane A2 antagonists TAISHO PHARMACEUTICAL CO., LTD. (JP) 1993-02-23 US disclosed
EP-0469901-A1 Sulfonamide derivatives TAISHO PHARMACEUTICAL CO. LTD (JP) 1992-02-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180200391-A1 NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR GRM3, GRM1, GRIN3A ALDH1A1 2376/4885HSD17B10 2229/4885CYP1A2 3393/4885
US-10335503-B2 Compound that specifically binds to AMPA receptor GRM3, GRIN3A, GRM1 ALDH1A1 2218/4885HSD17B10 2432/4885CYP1A2 2884/4885
US-20200384134-A1 IMAGING METHOD OF AMPA RECEPTORS IN BRAIN OF PRIMATE ORGANISM, PROGRAM, DIAGNOSTIC AGENT, COMPANION DIAGNOSTIC AGENT, DRUG, SCREENING METHOD, INPUT TERMINAL, SERVER AND SYSTEM SLC1A2, SLC1A1, SLC1A3 ALDH1A1 1454/4885HSD17B10 4041/4885CYP1A2 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.